Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 819 across all filing types
Latest filing 2026-01-23 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT: APPOINTMENT OF DIRECTOR BY LEGEND BIOTECH CORPORATION
Board/Management Information Classification · 1% confidence The document is a voluntary announcement regarding the appointment of a director at an associate company (Legend Biotech Corporation). It details the change in board composition, specifically the appointment of Mr. Jiange Meng to replace Dr. Li Zhu. This falls under the category of board or management changes.
2026-01-23 English
VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 DECEMBER 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Genscript Biotech Corporation regarding the preliminary sales figures of a specific product (CARVYKTI) for the quarter ended 31 December 2025. It references a Form 6-K filed by an associate company (Legend Biotech) and provides the sales data as a highlight. Since this is an initial announcement of specific financial performance metrics (sales figures) rather than a full quarterly report or a report publication announcement, it fits the definition of an Earnings Release (ER).
2026-01-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for issuers to report monthly movements in securities, including share capital, issued shares, and share options. Since it details changes in share capital and issued shares, it falls under the category of 'Share Issue/Capital Change'.
2026-01-05 English
GRANT OF SHARE AWARDS
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Genscript Biotech Corporation regarding the 'Grant of Share Awards' to directors, employees, and a service provider under existing RSU schemes. It details the number of shares, vesting periods, and performance conditions. This type of disclosure regarding share-based compensation and capital changes (issuance of new shares) falls under the category of share issues and capital changes.
2025-12-16 English
2021 Restricted Share Unit Scheme
Governance Information Classification · 1% confidence The document is a formal 'Restricted Share Unit Scheme' for GenScript Biotech Corporation. It outlines the rules, definitions, eligibility, and administration of an equity incentive plan for employees and service providers. This type of document is a governance and compensation policy document that is typically provided to shareholders as part of a proxy statement or as a standalone governance filing to explain how equity compensation is structured. Given the specific nature of the document as a 'Scheme' document (a legal framework for share-based compensation), it falls under Governance Information (CGR) as it defines the internal rules and structures for executive and employee compensation governance.
2025-12-16 English
2019 Restricted Share Unit Scheme
Governance Information Classification · 1% confidence The document is a formal 'Restricted Share Unit Scheme' for GenScript Biotech Corporation. It outlines the rules, definitions, governance, and administrative procedures for an equity incentive plan. This type of document is a governance and compensation policy document that defines how the company manages its share-based remuneration. In the context of the provided categories, this falls under 'Governance Information' (CGR) as it details the internal rules and structure of a corporate scheme, or 'Regulatory Filings' (RNS) as a general corporate announcement. Given the specific nature of the document as a formal scheme document, 'CGR' is the most accurate classification for internal governance and policy documentation.
2025-12-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.